|Awarded On||August 24, 2018|
|Title||Chemoprevention of Colon Cancer Progression in FAP Children|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||University of Houston|
|Principal Investigator/Program Director||Ming Hu|
Familial Adenomatous Polyposis (FAP) is a rare form of hereditary colon cancer predisposition that affects children as young as age 7. There is no drug treatment for FAP. The current standard of care is periodic colonoscopy to remove polyps and the removal of the whole colon to prevent the colon cancer development in adolescence, severely affecting their quality of life. Previously celecoxib was approved to treat FAP, but was withdrawn due to increased incidences of heart attack and death. The toxicities of celecoxib were due to its actions on the organs other than the target (colon). The goal of this research project is to develop a new class of COX-2 inhibitors that will only be active in ...